Publications by authors named "Adina Hughes"

Claim this Profile
K
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.
Ana Galan-Cobo, Natalie I Vokes, Yu Qian, David Molkentine, Kavya Ramkumar, Adina Hughes

Cancer Cell· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Adina Hughes

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
Ankur Karmokar, Rebecca Sargeant, Adina M Hughes, Hana Baakza, Zena Wilson

Cancers (Basel)· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, Urszula M Polanska, Marta Palafox, Adina Hughes

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Alexey Revenko, Larissa S Carnevalli, Charles Sinclair, Ben Johnson, Alison Peter, Adina M Hughes

J Immunother Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Zena Wilson, Rajesh Odedra, Yann Wallez, Paul W G Wijnhoven, Adina M Hughes

Cancer Res· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.
Larissa S Carnevalli, Molly A Taylor, Matthew King, Anna M L Coenen-Stass, Adina M Hughes

Mol Cancer Ther· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Theresa A Proia, Maneesh Singh, Richard Woessner, Larissa Carnevalli, Gayathri Bommakanti, Adina Hughes

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically.
Lucy C Riches, Antonio G Trinidad, Gareth Hughes, Gemma N Jones, Adina M Hughes

Mol Cancer Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Molly A Taylor, Adina M Hughes, Josephine Walton, Anna M L Coenen-Stass, Lukasz Magiera

J Immunother Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma.
Nicolas Floc'h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S Carnevalli, Adina M Hughes

Mol Cancer Ther· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in -mutant mammary tumours.
Liliana D Ordonez, Trevor Hay, Robert McEwen, Urszula M Polanska, Adina Hughes

Oncotarget· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8 T-cell activity.
Larissa S Carnevalli, Charles Sinclair, Molly A Taylor, Pablo Morentin Gutierrez, Sophie Langdon, Adina Hughes

J Immunother Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Alice Lallo, Kristopher K Frese, Christopher J Morrow, Robert Sloane, Sakshi Gulati, Adina Hughes

Clin Cancer Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity.
Sophie Langdon, Adina Hughes, Molly A Taylor, Elizabeth A Kuczynski, Deanna A Mele

Oncoimmunology· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 2.
Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, Simon T Barry, Darren A E Cross, Adina M Hughes

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: part 1.
Bénédicte Delouvrié, Katherine Al-Kadhimi, Jean-Claude Arnould, Simon T Barry, Darren A E Cross, Adina M Hughes

Bioorg Med Chem Lett· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis